Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Microscope in a BioEscalator Lab

News

CardiaTec joins the BioEscalator - AI in cardiovascular drug discovery

The BioEscalator welcomes CardiaTec, a spin-out company from the University of Cambridge that employs computational methods to decode the biology behind cardiovascular disease.

MediMabBio - Two time zones, one mission

Two clocks are visible behind the Chief Scientific Officer of MediMabBio, Dr Chris Willberg, as he sits in the company office at the BioEscalator – showing time zones seven hours apart, they are a reminder of how teams in Seoul and Oxford are working together to discover new treatments for cancer and autoimmune disease.

Exogene Announces Strategic Collaboration with Immunocore To Engineer T-Cell Receptors Using Artificial Intelligence

Exogene is excited to announce a research collaboration with TCR therapy industry leader Immunocore, developer of a novel class of TCR-based bispecific treatments for oncology, infectious diseases and autoimmune diseases using their proprietary ImmTAX technology. The purpose of the collaboration is to accelerate the discovery of high-affinity TCRs, with a vision to ultimately accelerate the development of TCR-based bispecific therapies across multiple targets and indications.

BioEscalator Team
Photograph of the BioEscalator building and adjoining carpark, taken from the top of the Kennedy building © BioEscalator Oxford